Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review.

about

Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review.

Item

http://www.wikidata.org/entity/Q50108035

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Potential Risks Related to Mod ...... gnalling: A Systematic Review.

@en

Potential Risks Related to Mod ...... gnalling: A Systematic Review.

@nl

type

Item

label

Potential Risks Related to Mod ...... gnalling: A Systematic Review.

@en

Potential Risks Related to Mod ...... gnalling: A Systematic Review.

@nl

prefLabel

Potential Risks Related to Mod ...... gnalling: A Systematic Review.

@en

Potential Risks Related to Mod ...... gnalling: A Systematic Review.

@nl

P1476

Potential Risks Related to Mod ...... gnalling: A Systematic Review.

@en

P2093

Amir Sharafkhaneh

http://www.w3.org/2001/XMLSchema#string

Gene Colice

http://www.w3.org/2001/XMLSchema#string

Martin Braddock

http://www.w3.org/2001/XMLSchema#string

Mats Carlsson

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system

Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma

IL-4 and IL-13 signaling in allergic airway disease

Immune Modulation of Cardiac Repair and Regeneration: The Art of Mending Broken Hearts

Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses

IL-13 from intraepithelial lymphocytes regulates tissue homeostasis and protects against carcinogenesis in the skin

Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer.

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.

Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials.

P2888

s40264-017-0636-9

P304

489-509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S40264-017-0636-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nicola A Hanania

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29411337

http://www.w3.org/2001/XMLSchema#string

P921

peptide

Interleukin 13

P932

5938313

http://www.w3.org/2001/XMLSchema#string